- Clinical Trials
Genprex is once again leading the way in gene therapy and raising the standard in cancer treatment based upon its unique, proprietary technology platform that includes its non-viral vector nanoparticle delivery system.
Researchers at Johns Hopkins Medicine recently published a study in Science Advances that introduces a non-viral delivery system for gene editing. Genprex has already treated more than 50 patients in Phase I and II clinical trials using its proprietary non-viral delivery system.
Five companies in the past week reported more than $54 million in funding deals and securities offerings.